Effects of neridronate treatment in elderly women with osteoporosis

Journal of Endocrinological Investigation

Volumn 28, Issue 5, 2005, Pages 202-208

  Cascella, T ^a   Musella, T ^a   Orio Jr , F ^a   Palomba, S ^b   Bifulco, G ^a   Nappi, C ^a   Lombardi, G ^a   Colao, A ^a   Tauchmanova, L ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Bone mineral density; Bone turnover; Elderly women; Neridronate; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; NERIDRONIC ACID; OSTEOCALCIN; VITAMIN D; 6 AMINO 1 HYDROXYHEXANE 1,1 DIPHOSPHONATE; 6-AMINO-1-HYDROXYHEXANE-1,1-DIPHOSPHONATE; BISPHOSPHONIC ACID DERIVATIVE;

AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ELDERLY CARE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT FUNCTION; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; QUALITY OF LIFE; STATISTICAL ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; MALE; PILOT STUDY; PSYCHOLOGICAL ASPECT; RADIODENSITOMETRY; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; BONE DENSITY; DENSITOMETRY, X-RAY; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PILOT PROJECTS; QUALITY OF LIFE;

EID: 21444431544     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345373     Document Type: Article

References (50)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348: 1535-41.
2. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282: 1344-52.
3. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002, 23: 570-8.
4. Marcus R, Wong M, Heath H III, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as endpoint. Endocr Rev 2002, 23: 16-37.
5. Fleisch H. Bisphosphonates - mechanism of action. Endocr Rev 1998, 19: 80-100.
6. Okolicsanyi L, Dal Bo N. The gastrointestinal tolerability of bisphosphonates. Aging Clin Exp Res 2001, 13: 344-6.
7. Adami S., Zamberlan N. Adverse effects of bisphosphonates - a comparative review. Drug Saf, 1996, 14: 158-70.
8. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987, 41: 326-31.
9. McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA. Comparative effects of intravenous bisphosphonates on calcium and skeletal metabolism in man. Bone 1987, 8 (Suppl 1): S35-41.
10. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346: 653-61.
11. Thiébaud D, Burckardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997, 103: 297-8.
12. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporosis Int 2003, 14: 801-7.
13. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in post-menopausal osteoporosis. J Clin Endocrinol Metab 1994, 79: 1595-9.
14. Gatti D, Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging 1999, 15: 285-96.
15. Widler L, Jaeggi KA, Glatt M, et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002, 45: 3721-38.
16. Frediani B, Spreafico A, Capperucci C, et al. Long-term effects of neridronate on human osteoblastic cell cultures. Bone 2004, 35: 859-69.
17. Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003, 18: 126-30.
18. Atkins RM, Yates AJ, Gray RE, et al. "Aminohexane diphosphonates in the treatment of Paget's disease of bone". J Bone Miner Res 1987, 2: 273-9.
19. Delmas PD, Chapuy MC, Edouard C, Meunier PJ. Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am J Med 1987, 83: 276-82.
20. Adami S, Bevilacqua M, Broggini M, et al. Short-term intravenous therapy with neridronate in Paget's disease. Clin Exp Rheumatol 2002, 20: 55-8.
21. O'Rourke NP, McCloskey EV, Rosini S, Coleman RE, Kanis JA. Treatment of malignant hypercalcemia with aminohexane bisphosphonate (neridronate). Br J Cancer 1994, 69: 914-7.
22. Morabito N, Gaudio A, Lasco A, et al. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res 2004, 19: 1766-70.
23. Tobias JH, Laversuch CJ, Chambers TJ, Gallagher AC. Aminohexane bisphosphonate suppress bone turnover in postmenopausal women more rapidly than oestrogen-gestagen therapy. Br J Rheumatol 1996, 35: 636-41.
24. Braga V, Gatti D, Colapietro F, et al. Intravenous neridronate in the treatment of postmenopausal osteoporosis. Bone 2003, 33: 342-5.
25. World Health Organization Study Group. (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. WHO, Geneve.
26. Minne HW, Leidig G, Wüster C, et al. A newly defined spine deformity index (SDI) to quantitative vertebral crush fractures in patients with osteoporosis. Bone Miner 1988, 3: 335-49.
27. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30: 473-83.
28. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, New England Medical Centre, Boston. 1993.
29. Apolone G, Mosconi P. The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 1998, 51: 1025-36.
30. th ed. Washington: American Psychiatric Association, DC. 1994.
31. Spitzer RL, Williams JBW, Gibbon M, Willams JBM. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version: User's Guide. Washington: American Psychiatric Association Press, DC. 1996.
32. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998, 339: 947-52.
33. Tauchmanovà L, Ricci P, Serio B, et al. Effect of intravenous zoledronic acid administration in patients with low bone mineral density and/or fast bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2005, 90: 627-34.
34. Passeri M, Baroni MC, Pedrazzoni M, et al. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner Res 1991, 15: 237-48.
35. Sartori L, Adami S, Filipponi P, Crepaldi G. Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. Aging Clin Exp Res 2003, 15: 271-83.
36. Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of Ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996, 19: 527-33.
37. Pecherstofer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ. Administration of the bisphosphonate Ibandronato (BM 21.0955) by intravenous bolo injection. J Bone Miner Res 1996, 11: 587-93.
38. Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002, 25: 539-46.
39. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998, 22: 455-61.
40. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104: 1363-74.
41. Marshall D, Johnell O, Wedell H. Meta analysis of how well measures of bone mineral density predict occurrence of osteoporotic fracture. BMJ 1996, 312: 1254-9.
42. Cranney A, Welch V, Tugwell P et al. Responsiveness of endpoints in osteoporosis clinical trials- an update. J Rheumatol 1999, 26: 222-8.
43. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000, 85: 231-6.
44. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995, 338: 736-46.
45. Turner CH. Yield behaviour of cancellous bone. J Biomech Eng 1989, 111: 1-5.
46. Filipponi P, Cristallini S, Policani G, Schifini MF, Casciari C, Garinei P. Intermittent versus continous clodronate administration in postmenopausal women with low bone mass. Bone 2000, 26: 268-74.
47. Rossini M, Braga V, Gatti D, Gerardi D, Zamberlan N, Adami S. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone 1999, 24: 125-9.
48. Gnudi S, Lisi L, Fini M, Malavoglia N. Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women. Int J Tissue React 2001, 23: 33-7.
49. Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypro-pylidene bisphosphonate. J Bone Miner Res 1991, 10: 956-62.
50. La Montagna G, Malesci D, Tirri R, Valentini G. Successful neridronate therapy in transient osteoporosis of the hip. Clin Rheumatol 2005, 24: 67-9.